Loading…
MRKR
Marker Therapeutics, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 57055L206
$1.37-6.16%Price as of Aug 29, 18:36 UTC · updated once a day, after the close
Key metrics
- Market cap
- $22.84M
- P/E
- —
- Forward P/E
- —
- P/B
- 1.9x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.38
- ROE
- -76.87%
- Profit margin
- -245.51%
- Revenue growth
- —
- Beta
- 1.51
- 52-week high
- $2.46
- 52-week low
- $0.83
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -92.2% over 5Y.
today you would have $68.05▼ -93.2%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 24 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $1.49 | $3.11 | $5.50 | $2.70 | $9.50 | $14.50 | $28.80 | $55.50 | $39.20 | $38.80 | $72.00 |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CNSYCerenome Inc | $3.05 | 1.1x | 4.1x | — | -614.05% | $23.15M |
| ALLRAllarity Therapeutics, Inc. | $1.41 | — | 6.4x | — | -157.09% | $22.43M |
| JSPRJasper Therapeutics, Inc. | $0.70 | — | 14.0x | — | -255.04% | $23.28M |
| ABVCABVC Biopharma Inc | $0.83 |
About the company
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.
- 5
- Houston, United States
Company description provided by Yahoo Finance.